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The aim of the present research is to formulate and evaluate the gastroretentive floating drug delivery 
system of antihypertensive drug, propranolol HCl. Gastroretentive floating tablets (GRFT) were prepared 
by using a synthetic hydrophilic polymer polyethylene oxide of different grades such as PEO WSR 
N-12 K and PEO 18 NF as release retarding polymers and calcium carbonate as gas generating agent. 
The GRFT were compressed by direct compression strategy and the tablets were evaluated for physico-
chemical properties, in vitro buoyancy, swelling studies, in vitro dissolution studies and release mechanism 
studies. From the dissolution and buoyancy studies, F 9 was selected as an optimized formulation. The 
optimized formulation followed zero order rate kinetics with non-Fickian diffusion mechanism. The 
optimized formulation was characterised with FTIR studies and observed no interaction between the 
drug and the polymers.
Uniterms: Gastroretentive floating/ drug delivery system. Gastroretentive floating tablets/in vitro 
dissolution. Hydrophilic polymers/use in drug delivery system. Polyethylene oxide. Propranolol HCl/
delivery system.
O objetivo da presente pesquisa é o de formular e avaliar o sistema de liberação de fármaco gastrorretentivo 
flutuante, contendo o anti-hipertensivo, cloridrato de propranolol. Comprimidos gastrorretentivo flutuantes 
(GRFT) foram preparados utilizando um polímero hidrofílico sintético, o óxido de polietileno, de 
diferentes graus, tais como GE WSR N-12 K e GE 18 NF, como polímeros de retardamento de liberação, 
e carbonato de cálcio, como agente gerador de gases. Os GRFT foram comprimidos por compressão 
direta e avaliados para determinação das propriedades físico-químicas, flutuabilidade in vitro, estudos 
de inchamento, de dissolução in vitro e de mecanismo de liberação. Dos testes de dissolução e de 
flutuabilidade, selecionou-se F 9 como formulação otimizada. A formulação otimizada seguiu cinética 
de ordem zero, com mecanismo de difusão não-Fickiano. Essa formulação foi caracterizada por estudos 
de FTIR, não se observando interação entre o fármaco e os polímeros.
Unitermos: Retenção gástrica flutuante/sistema de liberação de fármaco. Comprimidos gastrorretentivo 
flutuante/dissolução in vitro. Polímeros hidrofílicos/uso em sistema de liberação de fármaco. Óxido de 
polietileno. Cloridrato de propranolol/ sistema de liberação.
INTRODUCTION
Oral dosage forms have been developed from the 
past four decades due to their significant therapeutic 
advantages such as ease of administration, patient 
compliance and flexibility in formulation (Srikanth et 
al., 2011a). Nowadays, the trend is going towards the 
preparation of novel controlled drug delivery systems, 
in which the active drug can be controlled for a longer 
period. However, in the controlled drug delivery, the 
drug absorption is inadequate and highly variable in 
the individuals due to its physiological variability such 
as gastrointestinal transit as well as gastric residence 
time (GRT) of the dosage forms (Srikanth et al., 2011a). 
Gastroretentive technology is an alternative to overcome 
this problem. Through this technology, the dosage form 
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can be able to remain in the gastric region for several 
hours and hence significantly prolonging the gastric 
residence time of drugs. Prolonged gastric retention 
improves bioavailability, reduces drug waste, and 
improves solubility of drugs that are less soluble in a high 
pH environment. It is also suitable for local drug delivery 
to the stomach and proximal small intestines (Chawla et 
al., 2003).
The gastric retention of the dosage forms can 
be achieved by several methods such as floatation, 
mucoadhesion, swellable system, hydrodynamically 
balanced system, sedimentation, expansion modified shape 
systems, and so on (Streubel, Siepmann, Bodmeier, 2006). 
Out of the techniques, floatation is the convenient and 
effective method for the gastric retention. Gastroretentive 
floating drug delivery systems (GRFDDS) can be buoyant 
in the gastric medium for prolonged period of time due to 
its lower bulk density compared to the gastric medium. 
While the system is floating on the gastric contents, the 
drug will be released constantly at a desired rate from 
the dosage form and the GRT will be enhance. Due to 
increase in the GRT of the dosage form, more amount 
of the drug can be released in the gastric region, so that 
improves the bioavailability of the drug and also a better 
control of fluctuations in the plasma drug concentrations 
(Mayavanshi, Gajjar, 2008) is achieved.
In the present investigation propranolol HCl (PPH) 
was selected as a model drug for the development of 
gastroretentive floating drug delivery systems. PPH, a type 
of drug known as a beta-blocker, is used in the treatment 
of high blood pressure, angina pectoris (chest pain, usually 
caused by lack of oxygen to the heart due to clogged 
arteries), changes in heart rhythm, prevention of migraine 
headache, hereditary tremors, hypertrophic subaortic 
stenosis (a condition related to exertional angina), and 
tumors of the adrenal gland (Tripathi, 2003). Cmax of PPH 
occurs about 1 to 4 h after an oral dose and its elimination 
half-life is 3-4 h. Due to its short half-life, conventional 
tablets have to be administered several times to get an 
optimum effect or else controlled drug delivery is the 
alternative. Due to the short half-life and insolubility in 
intestinal fluids (acid soluble basic drug), PPH has been 
selected as a drug candidate for developing gastro retentive 
dosage form (Srikanth et al., 2011b).
The objective of the present research is to prepare 
PPH gastroretentive floating drug delivery system 
with suitable release retarding agents and to evaluate 
its buoyancy properties. In the present work different 
grades of polyethylene oxides (PEO) such as PEO WSR 
N 12 K and PEO 18 NF were used as swelling as well 
as release retarding polymers. The molecular weight of 
PEO WSR N 12 K and PEO 18 NF is 1000 000 and 4300 
000 respectively. Calcium carbonate was used as gas 
generating agent.
MATERIAL AND METHODS
Material
Propranolol HCl was provided by Dr Reddy’s 
Laboratories Ltd (Hyderabad, India). PEO grades, calcium 
carbonate and magnesium stearate were obtained as gift 
samples from Unichem Laboratories Ltd (Goa, India). All 
other reagents and chemicals were of analytical grade.
Preparation of gastroretentive floating tablets 
(GRFT) of propranolol HCl
All the ingredients sufficient for a batch of 100 
tablets according to the formulae shown in Table I were 
accurately weighed and passed through the sieve #40. PPH 
was geometrically mixed with PEO until a homogeneous 
blend was achieved. Calcium carbonate was added to the 
above mixture and mixed for 5 min in a polybag. Blend 
was lubricated with presifted magnesium stearate (sieve 
# 60) for 3 min. The lubricated blend was evaluated for 
flow properties. The final blend was directly compressed 
into tablets on a 16-station rotary tablet punching machine 
(M/s. Cadmach Machinery Co. Pvt., Ltd., India) using 8 
mm round plain punches at the hardness of 4-6 kg/cm2.
Determination of flow properties of lubricated 
blend
Angle of repose method
Angle of repose was determined by fixed funnel and 
free standing cone method. A funnel with the end of the 
stem cut perpendicular to its axis of symmetry was fixed 
at a given height (h) above the graph paper placed on a flat 
horizontal surface. The gum powder was carefully poured 
through the funnel until the apex of the conical pile just 
touched the tip of the funnel. The radius of the base (r) 
of the pile was determined and the tangent angle of the 
repose (θ) was calculated by following equation (Banker, 
Anderson, 1991).
Tan θ = h/r
Determination of compressibility index, Hausner´s ratio
Compressibility index (C.I) and Hausner’s ratio of 
the lubricated blend was determined by measuring the 
Bulk density (BD) and Tapped density (TD) of a powder.
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The BD was determined by three tap method. An 
amount of powder equivalent to 10 g was accurately 
weighed, placed in a 100 mL measuring cylinder without 
compaction. The volume occupied was measured and 
the initial bulk density was calculated by the following 
equation (Carr, 1965).
 
Tapped density (TD) of a powder is the ratio of the 
mass of the powder to the volume occupied by the powder 
after a fixed number of taps. The tapped density of the 
powder represents its random dense packing (Carr, 1965).
An amount of powder equivalent to 10 g was 
accurately weighed, transferred into a 100 mL measuring 
cylinder and placed on to the tapped density tester 
(model C-TDA2, Campbell Electronics, Mumbai, India) 
and subjected to USP-II method i.e., 250 drops per 
minute with a drop height of 3 mm±10%. The volume 
of the powder bed was measured after each increment 
of 250 drops until the difference between succeeding 
measurements is less than 2%. The final volume was 
recorded and the tapped density was calculated by the 
following equation.
 
Hausner’s ratio was determined by dividing the 
tapped density (TD) by bulk density (BD), and Carr’s 
compressibility index (CI) was determined using 
following equation (Carr, 1965).
 
Evaluation of the tablets
The floating tablets were evaluated for physico 
chemical parameters like weight variation, hardness, 
friability & assay, buoyancy characteristics, swelling 
studies, in vitro dissolution studies and release mechanism 
studies.
Weight variation
Twenty tablets were selected at randomly and 
weighed individually for the determination of weight 
variation of tablets. The mean and standard deviation were 
determined (Indian Pharmacopoeia, 2007).
Hardness test
Five tablets were selected at random and the 
hardness of each tablet was measured on Monsanto 
hardness tester.
Friability test
The friability test was carried out in Roche 
Friabilator. Twenty tablets were weighed (Xo) initially 
and put in a rotating drum. They were subjected to 100 
falls of 6 inches height (25 rpm for four minutes). After 
complete rotations the tablets were dedusted by using 
camel hairbrush and weighed (X). The percent loss in 
weight or friability (f) was calculated by the formula given 
in the following equation: (Carr, 1965)
 
Assay
From each batch, 10 tablets were randomly collected 
and powdered in a glass mortar. Accurately weighed 80mg 
of the powder was transferred into a 100 mL volumetric 
flask. The drug was extracted with 50 mL of 0.1 N HCl 
with vigorous shaking on a mechanical shaker for 1 h and 
filtered into a 100 mL volumetric flask through 0.45 µm 
Millipore nylon filter disc and the filtrate was made up to 
the mark with 0.1 N HCl. Further appropriate dilutions 
were made and the absorbance was measured at 289 nm 
against blank (0.1 N HCl).
TABLE I - Formula of propranolol HCl gastroretentive floating tablets. PEO: polyethylene oxide.
Ingredients (mg) F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 F 10
Propranolol HCl 80 80 80 80 80 80 80 80 80 80
PEO WSR N-12 K 80 160 240 280 320 - - - - -
PEO 18 NF - - - - - 60 80 100 120 140
Calcium carbonate 18 27 36 40 45 15.5 18 20 23 25
Magnesium stearate 2 3 4 4 5 1.5 2 2 2 2
Tablet weight (mg) 180 270 360 404 450 157 180 202 225 247
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Floating characteristics
All the formulated floating tablets were subjected to 
floating studies and for each batch 5 tablets were used. The 
in vitro buoyancy was determined by floating lag time, as 
per the method described by Srikanth et al. (2011c). The 
tablets were placed in a 900 mL beaker containing 0.1 N 
HCl. The time required for the tablet to rise to the surface 
and float was determined as floating lag time. The duration 
of time the dosage form constantly remained on the surface 
of medium was determined as total floating time (Srikanth 
et al., 2011c).
Swelling studies
The swelling ability of the GRFT was determined 
in 900 mL of acidic medium (0.1 N HCl) at room 
temperature. Weighed tablet was immersed in the medium 
and it was removed periodically from the medium. After 
draining the free water, the tablets were measured for 
weight gain. Swelling index (% SI) was expressed by the 
following equation (Debajyoti, Amresh, 2010).
In vitro dissolution studies
The release of propranolol HCl from floating 
tablets was determined by using Dissolution Tester USP 
XXIII (LABINDIA, Disso 200). The dissolution test was 
performed using 900 mL 0.1 N HCl solution at 37 ± 0.5 
°C and the paddles were rotated at 50 rpm. At appropriate 
time interval, 5 mL of aliquot was withdrawn from the 
dissolution medium and it was replaced with fresh medium 
to maintain the volume constant. The samples were filtered 
and diluted to suitable concentrations with 0.1 N HCl. 
The absorbance of the solutions were measured at 289 
nm for propranolol HCl with a UV-Visible double beam 
spectrophotometer (Elico SL210, India). Cumulative 
percentage drug release was calculated using an equation 
obtained from standard curve. The dissolution experiments 
were done in triplicate.
Release kinetics
There are number of kinetic models are available to 
describe the overall release of drug from the dosage forms. 
The dissolution profiles of all the batches were fitted to 
zero order, first order, Higuchi, Hixon-Crowell (erosion) 
and Korsemeyer-Peppas to ascertain the kinetic modelling 
of drug release (Lazarus, Cooper, 1961; Wagner, 1969; 
Higuchi, 1963; Korsmeyer, Gurny, Peppas, 1983; Hixson, 
Crowell, 1931).
The order of drug release from matrix systems 
was described by using zero order kinetics or first orders 
kinetics. The mechanism of drug release from matrix 
systems was studied by using Higuchi or erosion equation. 
The ‘n’ value is obtained as a slope for different batches 
of matrix tablets by plotting log percent drug dissolved 
against log time. If the value of n = 0.45 indicates 
Fickian (case I) release; >0.45 but <0.89 for non-Fickian 
(anomalous) release; and > 0.89 indicates super case II 
transport. Case II generally refers to the erosion of the 
polymeric chain and non-Fickian diffusion refers to a 
combination of both diffusion and erosion mechanism 
from the controlled drug release tablets.
Characterization of the optimized formulation
Formulations were optimized based on the 12 h 
drug retarding property, minimal polymer quantity and 
well buoyancy properties. Optimized formulation was 
further characterized with Fourier transformation-infrared 
spectroscopy (FTIR) for interaction studies.
Fourier transformation-infrared spectroscopy 
(FTIR)
FTIR was used to identify if there is any drug 
excipient interaction. FTIR studies were performed on 
drug, polymer and optimized formulation. Samples were 
analyzed by potassium bromide pellet method in an IR 
spectrophotometer (Shimadzu, FTIR 8700) in the region 
between 3500-500 cm-1.
RESULTS AND DISCUSSION
Pre-compression studies
Direct compression technique was used for the 
preparation of the floating tablets. Flow characteristics of 
Model Equation
Zero-order Qt = Q0 + k0t
First-order InQt = InQ0 – k1t
Higuchi Qt = kH√t
Hixon-Crowell Q01/3 – Qt1/3 = kst
Korsmeyer-Peppas Qt/Q∞ = kktn
Qt: amount of drug released in time t, Q0: initial amount of 
drug in the Tablet, Qt/Q∞: fraction of drug released at time 
t, k0; k1; kH; kk; ks: release rate constants, n: the release 
exponent indicative of the mechanism of drug release.
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the material being compressed are important parameter 
and hence studies were undertaken for the evaluation 
of flow characteristics of the lubricated blend used in 
the present study. The results of flow properties of the 
prepared lubricated blends are shown in Table II. The 
angle of repose values were within the range of 30-34° 
and 29-34° for PEO WSR N-12 K and 18 NF based 
formulations respectively indicated good flow properties. 
The compressibility index and Hausner’s ration of all the 
formulations were in the range of 12-14 and 1.11 to 1.15 
respectively indicated that flow properties of the blends 
were good.
Tableting properties
The results of the weight uniformity, hardness, 
friability as well as drug content are presented in Table III. 
It was observed all the formulations of PPH prepared 
using selected polymers PEO WSR N-12 K and PEO 18 
NF complied with compendia standard for uniformity of 
weight. The hardness for all the formulations was found 
to be in the range of 4-6 kg/cm2. The assay of the drug was 
>99%. The percentage weight loss in the friability test was 
found to be <0.5%. Thus, all the formulations were found 
to be of good quality fulfilling all the official requirements.
In vitro buoyancy studies
All the formulations were evaluated for in vitro 
buoyancy properties and results are mentioned in Table 
III. Floating lag time of PEO WSR N 12 K and PEO 18 
TABLE III - Tableting characteristics of propranolol HCl tablets
Formulation Weightx (mg) Assayy (%) Hardness* (kg/cm2) Friability** (%) FLT* (min) TFT
* (h)
PEO WSR N-12 K
F 1 180±1.51 98.12±1.4 4 - 6 0.12 9– 10 2
F 2 270±1.37 99.99±1.0 4 - 6 0.34 9 - 10 4
F 3 360±1.09 98.92±1.2 4 - 6 0.21 8 - 9 8
F 4 404±1.21 100.02±0.99 4 - 6 0.49 7 - 8 11
F 5 450±1.72 99.55±1.21 4 - 6 0.37 6 - 7 11
PEO 18 NF
F 6 157±1.12 99.99±1.77 4 - 6 0.42 5 - 6 4
F 7 180±1.06 99.91±1.86 4 - 6 0.29 4 - 5 6
F 8 202±1.21 98.01±1.22 4 - 6 0.49 3 - 4 10
F 9 225±1.09 99.96±1.45 4 - 6 0.22 2 - 3 12
F 10 247±1.22 100.67±1.23 4 - 6 0.39 1 - 2 14
x: mean ± s.d. (n=20) ; y: mean ± s.d. (n=10); * n=5 ; ** n= 20 FLT: floating lag time; TFT: total floating time; PEO: polyethylene 
oxide.
TABLE II - Flow properties of lubricated blend
Formulation Angle of repose (°)
Compressibility 
Index (%)
Hausner´s 
ratio
F 1 30 12 1.12
F 2 31 12 1.14
F 3 32 13 1.14
F 4 33 12 1.12
F 5 34 14 1.15
F 6 30 14 1.12
F 7 34 14 1.13
F 8 33 13 1.11
F 9 30 12 1.12
F 10 29 13 1.14
NF based formulations were found to be in the range of 
8-12 min and 1-6 min respectively. Total floating times 
of same based formulations were in the range of 4-12 h 
and 4-14 h respectively. From the buoyancy properties, 
it was observed that calcium carbonate is essential for 
the floating. Calcium carbonate liberates carbon dioxide, 
when it contact with acidic medium. The gas generated is 
trapped and protected within the gel formed by hydration 
of the PEO, thus decreasing the density of the tablet 
below 1 g/mL, and the tablet becomes buoyant (Srikanth 
et al., 2012a). Both grades of PEO are readily swellable 
polymers; this made the tablets buoyant in less time. PEO 
WSR 18 NF based formulations floated rapidly than PEO 
WSR N- 12 K.
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Swelling studies
The swelling studies of the floating tablets were 
conducted for 12 h. Swelling index of the all formulations 
was exhibited in the range of 74-102 %. From the swelling 
results, it is confirmed that swelling index is depended 
upon the quantity of the polymer and exposure time of the 
tablet to the medium. The swelling of the floating tablet 
has been increased gradually along with the time and 
it reached to saturation at particular time depends upon 
the quantity of the polymer it has (Swarna et al., 2012). 
Results showed that the swelling index increases with 
increased in concentration of PEO (Figure 1).
In vitro dissolution studies
The results of dissolution studies of formulation F 
1-F 5 and F 6-F 10 containing increased concentrations 
of PEO WSR N-12 K and PEO 18 NF respectively were 
shown in Figures 2 and 3, respectively. PEO WSR N-12 
K based formulations (F 1-5) containing drug to polymer 
ratios 1:1, 1:2, 1:3, 1:3.5 and 1:4 released 29.44, 22.13, 
19.74, 17.32 and 14.56% of the active drug at the end 
of 1h and retarded the drug up to 6, 8, 10, 12 and 14 h 
respectively. Another grade PEO polymer PEO 18 NF, 
having high molecular weight, was used for the gastric 
retention of the active drug. As the concentration of 18 
NF increased, the drug retardation is also increased. The 
formulations F6, F7, F8, F9 and F10 showed maximum 
drug release at 6, 8, 10, 12 and 14 h respectively. The 
formulation F 9 showed excellent buoyancy properties and 
retarding properties than all other formulations.
From all the above results it was concluded that the 
drug retardation is mainly depends up on the concentration 
of the polymer as well as swelling property of the polymer. 
Molecular weight of the polymer was also played a major 
role in the drug retardation (Srikanth et al, 2012b). It 
was observed that polymer with high molecular weight 
FIGURE 1 - Swelling index of propranolol HCl GRFT. PEO: polyethylene oxide.
FIGURE 2 - Dissolution profile of propranolol HCl GRFT by PEO WSR N-12K. PEO: polyethylene oxide.
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retarded drug efficiently than the polymer with lower 
molecular weight. The order of the drug retarding capacity 
of the polymer and their drug-polymer ratio was as follows 
PEO NF (1:1.5) > PEO WSR N-12 K (1:3.5). Even though 
positive results were obtained by F 4 formulated with 
PEO WSR N 12 K, F 9 formulated with PEO 18 NF was 
selected as an optimized formulation as the same desired 
results were obtained with less quantity of the polymer 
besides its good buoyancy properties.
Release kinetics
All the formulations made with PEO WSR N-12 
K followed zero order kinetics with erosion mechanism. 
All PEO WSR 18 NF based formulations followed zero 
order rate kinetics except the F 6 formulation which 
followed first order rate kinetics. Formulations F 6 and 
F 7 followed erosion mechanism with higher regression 
values of 0.9970 and 0.9853 respectively and remaining all 
formulations followed non Fickian diffusion mechanism. 
From the results, it was observed that as the concentration 
of the polymer increases, the release mechanism changed 
from erosion to diffusion. (Table IV).
Optimization
Based on the low polymer concentration, good 
buoyancy properties and drug retardation property up to 
12 h, the formulation F 9 was selected as an optimized. 
PEO 18 NF was selected as a suitable polymer for the 
development of gastro retentive floating drug delivery 
system of propranolol HCl.
Fourier transformation-infrared spectroscopy 
(FTIR)
The FTIR spectrum of PPH, PEO 18 NF and F 9 was 
shown in the Figure 4. The drug PPH showed characteristic 
TABLE IV - Rate order kinetics and release mechanism
Formulation
Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas
K0 r K1 r r r n r
F 1 16.348 0.9875 0.7038 0.9568 0.9839 0.9913 0.7574 0.9977
F 2 10.111 0.9847 0.3220 0.9655 0.9896 0.9912 0.6875 0.9944
F 3 8.3879 0.9863 0.2946 0.9341 0.9803 0.9893 0.6671 0.9934
F 4 7.8399 0.9952 0.1614 0.9762 0.9787 0.9914 0.6785 0.9847
F 5 7.0801 0.9983 0.1257 0.9712 0.9855 0.9927 0.8591 0.9914
F 6 17.1 0.9839 0.4535 0.9898 0.9790 0.9970 0.8477 0.9871
F 7 12.837 0.9912 0.3496 0.9635 0.9740 0.9853 0.8795 0.9959
F 8 8.902 0.9926 0.2437 0.9515 0.9859 0.9835 0.6876 0.9963
F 9 7.9968 0.9942 0.1911 0.9736 0.9862 0.9689 0.7076 0.9971
F 10 6.4698 0.9945 0.1225 0.9648 0.9996 0.9828 0.7259 0.9933
FIGURE 3 - Dissolution profile of propranolol HCl GRFT prepared by PEO 18 NF. PEO: polyethylene oxide.
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secondary amine –N–H stretching at 3278 cm-1, C-H 
stretching at 2959 cm-1, Aryl C=C stretching at 1584 cm-1, 
Aryl 0-CH2 asymmetric stretching at 1236 cm
-1 , Aryl 
O-CH2 symmetric stretching at 1034 cm-1 and the peak 
at 794 cm-1 due to α-substituted naphathalene (Venkata 
Srikanth et al., 2012) (Figure 4). The FTIR spectrum 
of PEO 18 NF showed the characteristic alcoholic –OH 
stretching at 3431 cm-1, -C-O-C asymmetric stretching at 
1251 cm-1 and -C-O-C symmetric stretching at 1048 cm-1.
Optimized PEO 18 NF based formulation (F 9) 
showed all the characteristic peaks of PPH with minor 
shifts in its FTIR spectrum. This spectrum showed 
secondary amine –N–H stretching at 3274 cm-1, C-H 
stretching at 2952 cm-1 , Aryl C=C stretching at 1577 cm-1 
, Aryl 0-CH2 asymmetric stretching at 1241 cm-1 , Aryl 
0-CH2 symmetric stretching at 1028 cm-1 and the peak at 
797 cm-1 due to α-substituted naphathalene (Figure 4). 
The results showed no significant change in the spectrum, 
indicating no interaction between the polymer and drug.
 
CONCLUSION
The gastroretentive floating drug delivery is a 
promising approach to achieve in vitro buoyancy by using 
hydrophilic polymers of polyethylene oxide grades such 
FIGURE 4 - FTIR spectra of (A) Propranolol HCl (B) PEO 18 
NF (C) formulation F 9.
as PEO WSR N 12 K, PEO 18 NF and gas-generating 
agent calcium carbonate. The results concluded that PEO 
WSR N-12 K and PEO 18 NF based formulations at the 
drug: polymer ratio 1:4 and 1:1.5 respectively retarded the 
drug release promptly than all other formulations. High 
molecular weight PEO grade exhibited higher retarding 
property and good buoyancy properties. The optimized 
formulation gives the best result in terms of the required 
floating lag time and total floating time. Optimized 
formulation (F 9) when characterized with FTIR studies 
showed no interactions between drug and polymer. Hence, 
it can be concluded that, PEO is a suitable polymer for 
the development of gastroretentive floating drug delivery 
systems.
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